0001493152-22-031673.txt : 20221114 0001493152-22-031673.hdr.sgml : 20221114 20221114084802 ACCESSION NUMBER: 0001493152-22-031673 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20221114 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera Inc. CENTRAL INDEX KEY: 0001858685 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473765675 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40943 FILM NUMBER: 221380738 BUSINESS ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-245-1325 MAIL ADDRESS: STREET 1: 120 PRESIDENTIAL WAY, STREET 2: SUITE 330 CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 form8-k.htm
0001858685 false 0001858685 2022-11-14 2022-11-14 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2022-11-14 2022-11-14 0001858685 BFRI:PreferredStockPurchaseRightsMember 2022-11-14 2022-11-14 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2022-11-14 2022-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 14, 2022

 

Biofrontera Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40943   47-3765675

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

120 Presidential Way, Suite 330

Woburn, Massachusetts

   01801
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 245-1325

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 per share   BFRI   The Nasdaq Stock Market LLC
         
Preferred Stock Purchase Rights       The Nasdaq Stock Market LLC
         
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share   BFRIW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 14, 2022, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the third quarter ended September 30, 2022. A copy of the press release is being furnished as Exhibit 99.1 attached hereto to this Current Report on Form 8-K.

 

The Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

 

The information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1   Press release dated November 14, 2022
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

November 14, 2022 Biofrontera Inc.
(Date) (Registrant)
   
  /s/ Erica L. Monaco
  Erica L. Monaco
  Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Logo, company name Description automatically generated

 

PRESS RELEASE

 

Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business Update

 

Conference call begins at 11:00 a.m. Eastern time today

 

WOBURN, Mass. (November 14, 2022) – Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and nine months ended September 30, 2022 and provided a business update.

 

Highlights from the third quarter of 2022 and subsequent weeks include the following:

 

Financial Highlights

 

  ● Total revenues for the third quarter of 2022 were $4.3 million, consistent with the third quarter of 2021
  ● Total revenues for the first nine months of 2022 were $18.5 million, an increase of 24% from the comparable prior-year period
  ●  Cash and cash equivalents were $27.5 million as of September 30, 2022, compared with $24.5 million as of December 31, 2021
  ● Raised $4.3 million in net proceeds from the exercise of existing warrants and the issuance of new warrants through a private placement transaction
  ● Strengthened and aligned the mutually beneficial relationship between Biofrontera Inc. and Biofrontera AG through an acquisition of Biofrontera AG shares
  ● Adopted a limited duration shareholder rights plan and declared a dividend distribution of preferred stock purchase rights

 

Clinical and Business Highlights

 

  ● Strengthened medical affairs through various initiatives including seminars, medical conferences, prescriber networking and key opinion leader (KOL) engagement

 

  ○ Showcased Ameluz® for the treatment of actinic keratosis (AK) in four poster presentations at the 2022 Fall Clinical Dermatology Conference, where the Company also served as a Gold Industry Sponsor
  ○ Sponsored an Advisory Board meeting at the Fall Clinical Dermatology Conference consisting of two sessions that provided advanced education on the advantages and current landscape of photodynamic therapy (PDT) and shared real-world PDT utilization experiences by leading clinicians

 

  ● Biofrontera Bioscience GmbH was granted a patent in Australia for novel illumination protocols related to the treatment of skin diseases with PDT that combine the lower pain of daylight PDT with the higher cure rates and lower recurrence rates of conventional therapy

 

1
 

 

  ● Biofrontera Pharma GmbH received notice of allowance from the United States Patent and Trademark Office for the preparation of nanoemulsions or compositions, describing its use in the treatment of dermatological, virus-associated and cell proliferation diseases, as well as in cosmetics
  ● Ameluz new marketing campaign earned “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards, and Associate Director of Marketing Leslie Hopkins was named 2022 Brand Champion for Dermatology, all by PM360, a publication for marketing decision markets in the pharmaceutical, biotech, diagnostics and medical device industries
  ● Named Fred Leffler as Chief Financial Officer, bringing to Biofrontera significant leadership, financial management, consulting and operations experience
  ● Appointed Gerard DiGirolamo as National Sales Director to strengthen our salesforce and execute on our commercial plan and launch planning of BF-RhodoLED XL®

 

Management Commentary

 

“During the third quarter and recent weeks we strengthened our medical affairs initiatives with sponsorship, participation and presentation of our innovative dermatology solutions. Through peer-to-peer interactions and other activities, dermatologists are increasingly choosing our brands for their patients. The variety of our activities and our visibility in the dermatology sector are sharpening our corporate profile as an innovative dermatology company and emphasizing our strong commitment to improving patient care in collaboration with dermatologists. Our success in strengthening patent protection for our products justifies continued investments in marketing and further clinical development,” stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. “Key strategic hires including a CFO and a national sales director will support our continued success. With year-to-date revenues up 24%, we expect total revenues for 2022 to increase between 24% and 31% compared with 2021, inclusive of seasonal strength in the first and fourth quarters. We expect to close 2022 with demonstrated market-share gains as well as with an operational foundation that will position us for increased ROI in 2023.”

 

Third Quarter Financial Results

 

Total revenues for the third quarter of 2022 of $4.3 million were consistent with the third quarter of 2021.

 

Total operating expenses were $8.0 million for the third quarter of 2022, compared with $20.4 million for the third quarter of 2021. Cost of revenues decreased by 3% primarily due to lower Ameluz sales. Selling, general and administrative expenses decreased by $9.3 million, or 54%, compared with the prior year primarily due to a one-time legal settlement expense in 2021, partially offset by higher business insurance and headcount costs as a result of resumed hiring in 2022.

 

Net loss for the third quarter of 2022 was $2.6 million, or $0.11 per share, compared with a net loss of $16.0 million, or $2.00 per share, for the third quarter of 2021.

 

Adjusted EBITDA was negative $5.0 million for the third quarter of 2022, compared with negative $3.8 million for the third quarter of 2021. Adjusted EBITDA, a non-GAAP financial measure, is defined as net income or loss excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items.

 

Nine Month Financial Results

 

Total revenues for the first nine months of 2022 were $18.5 million, compared with $14.9 million for the first nine months of 2021. The increase of $3.6 million, or 24%, was primarily driven by higher volume of Ameluz orders, which resulted in an increase in Ameluz revenue of $3.2 million, and by an Ameluz price increase, which increased Ameluz revenue by $0.2 million.

 

2
 

 

Total operating expenses were $31.5 million for the first nine months of 2022, compared with $38.3 million for the same period in 2021. Cost of revenues increased by 25% compared with the prior-year period primarily due to higher sales of Ameluz. Selling, general and administrative expenses decreased by $2.3 million, or 8%, primarily due to a one-time legal settlement expense in 2021, partially offset by higher business insurance and headcount costs as a result of resumed hiring in 2022.

 

Net income for the first nine months of 2022 was $2.1 million, or $0.11 per diluted share, compared with net loss of $23.2 million, or $2.90 per share, for the first nine months of 2021.

 

Adjusted EBITDA was negative $14.1 million for the first nine months of 2022, compared with negative $9.5 million for the same period in 2021.

 

The below table presents a reconciliation of net income (loss) to adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021:

 

   Three months ended
September 30,		   Nine months ended
September 30,		 
   2022   2021   2022   2021 
Net income (loss)   $(2,566)  $(16,012)  $2,145   $(23,208)
Interest expense, net   89    86    160    255 
Income tax expense   1    6    31    51 
Depreciation and amortization   130    134    394    409 
EBITDA   (2,346)   (15,786)   2,730    (22,493)
Change in fair value of contingent consideration   (2,200)   700    (4,100)   1,698 
Change in fair value of warrant liabilities   (1,185)   -    (15,267)   - 
Legal settlement expenses   -    11,250    -    11,250 
Stock-based compensation   400    -    1,469    - 
Expensed issuance costs   320    

-

    1,045    

-

 
Adjusted EBITDA  $(5,011)  $(3,836)  $(14,123)  $(9,545)
Adjusted EBITDA margin   -115.9%   -88.5%   -76.2%   -63.9%

 

As of September 30, 2022, Biofrontera Inc. had cash and cash equivalents of $27.5 million, compared with $24.5 million as of December 31, 2021. The Company believes its cash and cash equivalents are sufficient to fund operations for at least the next 12 months.

 

Financial Guidance

 

Biofrontera Inc. is revising its previously announced financial guidance for 2022, as follows:

 

  ● Total revenues for 2022 are expected to increase between 24% and 31% compared with 2021, including typical seasonal strength in the first and fourth quarters
  ● The commercial focus throughout 2022 will be on achieving deeper sales penetration among current customer accounts and increasing market share.

 

Conference Call and Webcast

 

Biofrontera Inc. will hold a conference call today at 11:00 a.m. Eastern time to discuss these results and answer questions.

 

Date: Monday, November 14, 2022
Time: 11:00 a.m. Eastern time
Conference call:

877-877-1275 (U.S.)

412-858-5202 (international)

Webcast: Live and 90-day replay webcast are available here and at investors.biofrontera-us.com

 

3
 

 

About Biofrontera Inc.

 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Biofrontera Inc.’s (the “Company”) revenue guidance for 2022, the Company’s relationship with Biofrontera AG (including beneficial ownership of Biofrontera AG’s shares and future collaboration between the Company and Biofrontera AG), business and marketing strategy, hiring strategy, development of medical affairs initiatives, growth of the Company’s profile, future operations and business, increased patent protection for our licensed products, potential to expand the label of Ameluz®, market presence and position of Ameluz® and ongoing clinical trials conducted by our licensing partners and the future impact of such trials on the market for Ameluz®. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

 

Contacts:

 

Biofrontera Inc.

Anke zur Mühlen

+1 781 486 1539

us-ir@biofrontera.com

 

LHA Investor Relations

Tirth T. Patel

+1 212 201 6614

tpatel@lhai.com

 

(Tables to follow)

 

4
 

 

BIOFRONTERA INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share amounts)

 

   September 30, 2022   December 31, 2021 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $27,518   $24,545 
Accounts receivable, net   1,562    3,784 
Other receivables, related party   3,503    8,647 
Inventories   12,087    4,458 
Prepaid expenses and other current assets   3,823    4,987 
           
Total current assets   48,493    46,421 
           
Other receivables long term, related party   2,813    2,813 
Property and equipment, net   224    267 
Intangible asset, net   3,136    3,450 
Other assets   393    268 
           
Total assets  $55,059   $53,219 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $253   $658 
Accounts payable, related parties   4,206    282 
Acquisition contract liabilities, net   3,242    3,242 
Accrued expenses and other current liabilities   9,442    9,654 
           
Total current liabilities   17,143    13,836 
           
Long-term liabilities:          
Acquisition contract liabilities, net   5,711    9,542 
Warrant liability   3,964    12,854 
Other liabilities   5,646    5,649 
           
Total liabilities  $32,464   $41,881 
           
Commitments and contingencies (see Note 23)          
           
Stockholders’ equity:          
Preferred Stock, $0.001 par value, 20,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2022, and December 31, 2021  $-   $- 
Common Stock, $0.001 par value, 300,000,000 shares authorized; 23,550,960 and 17,104,749 shares issued and outstanding as of September 30, 2022, and December 31, 2021   23    17 
Additional paid-in capital   99,306    90,200 
Accumulated deficit   (76,734)   (78,879)
           
Total stockholders’ equity   22,595    11,338 
           
Total liabilities and stockholders’ equity  $55,059   $53,219 

 

5
 

 

BIOFRONTERA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts and number of shares)

(Unaudited)

 

   Three months ended
September 30,		   Nine months ended
September 30,		 
   2022   2021   2022   2021 
                 
Products revenues, net  $4,290   $4,319   $18,467   $14,890 
Revenues, related party   32    15    63    42 
                     
Total revenues, net   4,322    4,334    18,530    14,932 
                     
Operating expenses                    
Cost of revenues, related party   2,127    2,249    9,504    7,630 
Cost of revenues, other   98    41    425    339 
Selling, general and administrative   7,765    17,090    25,050    27,412 
Selling, general and administrative, related party   171    160    612    520 
Restructuring costs   -    199    -    654 
Change in fair value of contingent consideration   (2,200)   700    (4,100)   1,698 
                     
Total operating expenses   7,961    20,439    31,491    38,253 
                     
Loss from operations   (3,639)   (16,105)   (12,961)   (23,321)
                     
Other income (expense)                    
Change in fair value of warrants   1,185    -    15,267    - 
Interest expense, net   (89)   (86)   (160)   (255)
Other income (expense), net   (22)   185    30    419 
                     
Total other income (expense)   1,074    99    15,137    164 
                     
Income (loss) before income taxes   (2,566)   (16,006)   2,176    (23,157)
Income tax expense   1    6    31    51 
                     
Net income (loss)  $(2,566)  $(16,012)  $2,145   $(23,208)
                     
Income (loss) per common share:                    
Basic  $(0.11)  $(2.00)  $0.11   $(2.90)
Diluted  $(0.11)  $(2.00)  $0.11   $(2.90)
                     
Weighted-average common shares outstanding:                    
Basic   22,725,821    8,000,000    19,560,351    8,000,000 
Diluted   22,725,821    8,000,000    19,605,014    8,000,000 

 

# # #

 

6

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 bfri-20221114.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 bfri-20221114_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bfri-20221114_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common stock, par value $0.001 per share Preferred Stock Purchase Rights Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 7 bfri-20221114_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 14, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2022
Entity File Number 001-40943
Entity Registrant Name Biofrontera Inc.
Entity Central Index Key 0001858685
Entity Tax Identification Number 47-3765675
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 120 Presidential Way
Entity Address, Address Line Two Suite 330
Entity Address, City or Town Woburn
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01801
City Area Code (781)
Local Phone Number 245-1325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Entity Information, Former Legal or Registered Name Not Applicable
Common stock, par value $0.001 per share  
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol BFRI
Security Exchange Name NASDAQ
Preferred Stock Purchase Rights  
Title of 12(b) Security Preferred Stock Purchase Rights
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share  
Title of 12(b) Security Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share
Trading Symbol BFRIW
XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001858685 2022-11-14 2022-11-14 0001858685 BFRI:CommonStockParValue0.001PerShareMember 2022-11-14 2022-11-14 0001858685 BFRI:PreferredStockPurchaseRightsMember 2022-11-14 2022-11-14 0001858685 BFRI:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember 2022-11-14 2022-11-14 iso4217:USD shares iso4217:USD shares 0001858685 false 8-K 2022-11-14 Biofrontera Inc. DE 001-40943 47-3765675 120 Presidential Way Suite 330 Woburn MA 01801 (781) 245-1325 Not Applicable false false false false Common stock, par value $0.001 per share BFRI NASDAQ Preferred Stock Purchase Rights NASDAQ Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share BFRIW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 4 25 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biofrontera.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm bfri-20221114.xsd bfri-20221114_def.xml bfri-20221114_lab.xml bfri-20221114_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "bfri-20221114_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "bfri-20221114_lab.xml" ] }, "presentationLink": { "local": [ "bfri-20221114_pre.xml" ] }, "schema": { "local": [ "bfri-20221114.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 67, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 3, "memberStandard": 0, "nsprefix": "BFRI", "nsuri": "http://biofrontera.com/20221114", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-14to2022-11-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://biofrontera.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-14to2022-11-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "BFRI_CommonStockParValue0.001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.001 per share" } } }, "localname": "CommonStockParValue0.001PerShareMember", "nsuri": "http://biofrontera.com/20221114", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_PreferredStockPurchaseRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Purchase Rights" } } }, "localname": "PreferredStockPurchaseRightsMember", "nsuri": "http://biofrontera.com/20221114", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "BFRI_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $5.00 per share" } } }, "localname": "WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf5.00PerShareMember", "nsuri": "http://biofrontera.com/20221114", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://biofrontera.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001493152-22-031673-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-031673-xbrl.zip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end